Fosamax Osteonecrosis of the Jaw Causation: Medical Literature on Fosamax-Associated ONJ Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Communication

The legacy of general health and science communication has long served as a foundation for public understanding of medical risks. Within this broad context, the dissemination of information regarding pharmaceutical therapies and their potential adverse effects has been a key focus. Historically, such communication aimed to inform patients and healthcare providers about the balance between therapeutic benefits and possible harms, often in a generalized manner. This heritage of health information sharing now provides a critical backdrop for examining more specific exposure scenarios. As we pivot from this general health context, attention turns to the occupational environment where exposure to certain substances may occur. In particular, the transition from broad pharmaceutical risk communication to a focused concern about workplace exposure is warranted. The case of bisphosphonate medications, such as Fosamax, and their association with osteonecrosis of the jaw exemplifies this shift. While initial health information addressed patient populations, the occupational setting introduces distinct considerations regarding chronic, low-level exposure and its potential consequences. This pivot acknowledges that the same agents discussed in general health contexts may present unique risks when encountered repeatedly in professional environments, thereby necessitating a more targeted examination of exposure pathways and risk profiles within occupational health frameworks.

Bridge to Fosamax and ONJ

Building on the legacy of general health communication, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes of jawbone lesions. The condition is considered a rare but serious adverse effect of antiresorptive therapy.

Mechanistic Pathways and Evidence

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates like Fosamax accumulate in bone tissue and inhibit osteoclast activity, which may impair bone remodeling and healing, particularly in the jawbone, which has high turnover rates. This suppression of bone turnover, combined with local factors such as dental procedures or infection, may lead to necrotic bone exposure. The timeline between exposure to Fosamax and documented harm varies. According to FDA-approved labeling, the time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, population-level data indicate that risk increases with longer exposure. A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). This suggests a cumulative dose-response relationship, where prolonged bisphosphonate use increases the likelihood of ONJ.

Risk Factors and Warnings

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the FDA-approved labeling for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. The labeling also advises discontinuation if severe symptoms develop and notes that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its occurrence in clinical trials was not significantly elevated compared to placebo, possibly due to the rarity of the event.

Causation Considerations and Management

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax use and ONJ onset, excluding other potential causes such as cancer or other medications, and evaluating the presence of known risk factors. The labeling indicates that ONJ can occur spontaneously but is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The cohort study data showing increased risk with longer exposure supports a causal link, though absolute risks remain low (https://pubmed.ncbi.nlm.nih.gov/39400702). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative dental care, and treatment of infection. The risk diminishes after discontinuation, as noted in the cohort study (https://pubmed.ncbi.nlm.nih.gov/39400702). In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw, with evidence from both clinical labeling and population-based studies. The risk increases with duration of use and is influenced by dental procedures and other factors. Warnings in the product labeling address this risk, but patients and healthcare providers should remain vigilant, particularly in those with prolonged exposure or undergoing invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for osteoporosis and Paget's disease. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with dental procedures or infection. Fosamax and other bisphosphonates can increase the risk of ONJ, especially with prolonged use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, and ill-fitting dentures. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in Fosamax users?

ONJ is rare. A cohort study found absolute risk about 0.05% after 5 years of treatment, but risk increases with longer use (threefold after 2-3 years, eightfold after 10 years) (https://pubmed.ncbi.nlm.nih.gov/39400702).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.